BASIL-2: Revascularization of Infra-Popliteal Territory in Patients with Critical Lower Limb Ischemia

Results of infrapopliteal territory revascularization in critical limb ischemia.


Compared against the general population, patients suffering from critical lower limb ischemia (CLI) not only experience seriously limited quality of life, but also face a significant higher risk of death and amputation. 

BASIL-2: Revascularización del territorio infrapopliteo en pacientes con isquemia crítica de miembros inferiores

Specifically, the optimal treatment for these patients remains uncertain. This uncertainty was sparked by the BASIL-1 (2005), which suggested the first treatment option for critical limb ischemia was a vein bypass, instead of a balloon angioplasty, despite the fact that only 25% of patients in that study had received infrapopliteal treatment. 

The aim of the BASIL-2 was to determine whether a surgical bypass was superior to an endovascular intervention in terms of amputation or death. This multicenter study was carried out mainly in the UK (39 of 41 centers). It included patients with over 6-month life expectancy, with infrapopliteal disease treatable both ways (excluding patients with prior treatment of index limb, within 12 months). 

The study randomized patients 1:1. Primary end point was amputation-free survival, defined as time to major amputation or all cause death. Secondary end points included time to all cause death, time to amputation, index limb major adverse events (MALE) and time to major cardiovascular event (MACE). 

Read also: TAVI in Moderate Aortic Stenosis with Low Ejection Fraction.

Between July 2014 and November 2020, 345 patients were recruited: 81% were men, mean age 72.5; 50% of patients received a venous bypass and the remaining half the best possible endovascular treatment. Patients were followed up to 40 months.

63% of bypass patients and 53% of endovascular patients died or received a major amputation (adjusted HR 1.35, CI 95% 1.02-1.80; p=0.037). Mean time to amputation was 3.3 years in the bypass group and 4.4 in the endovascular group. As regards global mortality, 53% of bypass patients and 45% of endovascular patients presented this outcome (adjusted HR 1.37, CI 95% 1.0-1.87). When looking at major amputation, there was also a higher number of events in the bypass group, though with no statistical significance (adjusted HR 1.23, CI 95% 0.75-2.01).

When looking at safety, reintervention rate was higher in the endovascular group (HR 0.27, CI 95% 1.13-0.55). There were no significant differences as regards MALE and MACE or quality of life according to HRQoL questionnaires. Major adverse events rate was higher among bypass patients (17% vs 13%).

Conclusions

BASIL-2 outcomes indicate vein bypass as a first revascularization strategy was associated to 35% increased risk in major amputation or death in patients with critical lower limb ischemia (infrapopliteal disease). This difference was mainly driven by a higher number of deaths. The number of primary end point events show the baseline severity of this disease, and therefore, we should emphasize the need for early treatment.  

These outcomes should be compared against the BEST-CLI (published in 2022), with different results as regards strategy. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Miember of the Editorial Board of SOLACI.org.

Original Title: A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2).

Reference: Bradbury, Andrew W et al. “A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.” Lancet (London, England) vol. 401,10390 (2023): 1798-1809. doi:10.1016/S0140-6736(23)00462-2.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...